TABLE 2.
Treatments | P value | ||||
---|---|---|---|---|---|
Compound | Control | Met | Treat | Time | Treat × Time |
Indispensable amino acids, μM | |||||
Ile | 100 ± 5.8 | 107 ± 5.8 | 0.417 | 0.007 | 0.607 |
Leu | 135 ± 6.5 | 140 ± 6.5 | 0.651 | 0.016 | 0.963 |
Lys | 54.6 ± 2.4 | 58.8 ± 2.4 | 0.692 | <0.001 | 0.643 |
Met | 9.43 ± 0.76 | 12.0 ± 0.76 | 0.027 | 0.441 | 0.750 |
Phe | 39.9 ± 1.2 | 39.7 ± 1.2 | 0.794 | 0.141 | 0.511 |
Thr | 60.9 ± 2.7 | 58.7 ± 2.7 | 0.717 | 0.022 | 0.140 |
Val | 213 ± 11.9 | 230 ± 11.9 | 0.339 | 0.001 | 0.937 |
Total | 652 ± 25 | 679 ± 25 | 0.344 | 0.006 | 0.101 |
Met as % of total | 1.54 ± 0.13 | 1.88 ± 0.13 | 0.114 | 0.003 | 0.983 |
Dispensable amino acids, μM | |||||
Ala | 182 ± 8.8 | 178 ± 8.8 | 0.750 | 0.017 | 0.070 |
Arg | 50.9 ± 2.0 | 49.7 ± 2.0 | 0.680 | <0.001 | 0.218 |
Asp | 9.59 ± 0.76 | 9.88 ± 0.76 | 0.793 | 0.007 | 0.842 |
Glu | 39.1 ± 2.0 | 41.2 ± 2.0 | 0.483 | 0.003 | 0.623 |
Gly | 297 ± 17.4 | 254 ± 17.4 | 0.095 | <0.001 | 0.195 |
Ser | 67.3 ± 3.2 | 63.9 ± 3.2 | 0.472 | 0.022 | 0.150 |
Tau | 29.9 ± 0.6 | 24.7 ± 0.6 | <0.001 | 0.980 | 0.512 |
BCAA, μM | 448 ± 24 | 477 ± 24 | 0.424 | 0.003 | 0.903 |
Total indispensable + dispensable, μM | 1652 ± 43 | 1631 ± 43 | 0.747 | 0.002 | 0.190 |
Met as % of total | 0.58 ± 0.04 | 0.75 ± 0.04 | 0.014 | 0.011 | 0.932 |
Lys as % of total | 5.76 ± 0.22 | 5.84 ± 0.22 | 0.811 | <0.001 | 0.626 |
Other compounds, μM | |||||
α-Aminobutyric acid | 16.6 ± 1.1 | 14.3 ± 1.1 | 0.053 | <0.001 | 0.252 |
Ornithine | 19.1 ± 1.7 | 19.4 ± 1.7 | 0.884 | 0.007 | 0.434 |
1-Methylhistidine | 14.0 ± 0.9 | 12.0 ± 0.9 | 0.094 | <0.001 | 0.353 |
3-Methylhistidine | 5.57 ± 0.49 | 4.06 ± 0.49 | 0.050 | <0.001 | 0.506 |
Values are means ± pooled SEMs, n = 10/treatment group. BCAA, branched-chain amino acid.